A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers

• Published in: Cancer prevention research (Philadelphia, Pa.) Vol. 12; no. 10; pp. 721 - 730
• Main Authors: Keith, Robert L., Blatchford, Patrick J., Merrick, Daniel T., Bunn, Paul A., Bagwell, Brandi, Dwyer-Nield, Lori D., Jackson, Mary K., Geraci, Mark W., Miller, York E.
• Format: Journal Article
• Language: English
• Published: United States 01.10.2019
• Subjects: Aged; Biopsy; Bronchopulmonary Dysplasia - drug therapy; Bronchopulmonary Dysplasia - pathology; Bronchoscopy; Carcinoma in Situ - pathology; Carcinoma in Situ - prevention & control; Chemoprevention - methods; Double-Blind Method; Female; Humans; Lung - drug effects; Lung - pathology; Lung Neoplasms - pathology; Lung Neoplasms - prevention & control; Male; Middle Aged; Pioglitazone - therapeutic use; Placebos; Remission Induction; Risk Factors; Smokers; Smoking - adverse effects; Smoking - drug therapy; Smoking Cessation - statistics & numerical data; Sputum - cytology; Sputum - drug effects

Lung cancer chemoprevention, especially in high-risk former smokers, has great potential to reduce lung cancer incidence and mortality. Thiazolidinediones prevent lung cancer in preclinical studies, and diabetics receiving thiazolidinediones have lower lung cancer rates which led to our double-blind...